Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

171 ta ish

Ish: Exploring cellular immunotherapy platforms in multiple myeloma

  1. Nano based drug delivery systems: recent developments and future prospects

    Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto +9

    Sharh maqola201811 iqtibos
    ABI

  2. Neoantigens: promising targets for cancer therapy

    Na Xie, Guobo Shen, Wei Gao +3

    Sharh maqola20236 iqtibos
    ABI

  3. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

    Maqola20215 iqtibos
    ABI

  4. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje, Jesús G. Berdeja, Yi Lin +20

    Maqola20194 iqtibos
    ABI

  5. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

    S. Vincent Rajkumar

    Maqola20224 iqtibos
    ABI

  6. Bispecific T‐cell engagers for cancer immunotherapy

    Amelia M. Huehls, Tiffany A. Coupet, Charles L. Sentman

    Sharh maqola20143 iqtibos
    ABI

  7. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model

    Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12

    Maqola20213 iqtibos
    ABI

  8. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

    Jianjun Chu, Youcai Deng, D.M. Benson +13

    Maqola20133 iqtibos
    ABI

  9. <i>In vivo</i> kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection

    Yan Zhang, Diana L. Wallace, Catherine M. de Lara +8

    Maqola20073 iqtibos
    ABI

  10. Clinical relevance of host immunity in breast cancer: from TILs to the clinic

    Peter Savas, Roberto Salgado, Carsten Denkert +4

    Sharh maqola20153 iqtibos
    ABI

  11. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

    Joseph D. Malaer, Porunelloor A. Mathew

    Maqola20173 iqtibos
    ABI

  12. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Stephen J. Schuster, Michael Bishop, Constantine S. Tam +21

    Maqola20183 iqtibos
    ABI

  13. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

    Na Tang, Chen Cheng, Xingying Zhang +6

    Maqola20203 iqtibos
    ABI

  14. CAR-NK cells: A promising cellular immunotherapy for cancer

    Guozhu Xie, Han Dong, Yong Liang +3

    Sharh maqola20203 iqtibos
    ABI

  15. Bispecifics, trispecifics, and other novel immune treatments in myeloma

    Guido Lancman, Joshua Richter, Ajai Chari

    Sharh maqola20203 iqtibos
    ABI

  16. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

    Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang +2

    Sharh maqola20213 iqtibos
    ABI

  17. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

    Ben Creelan, Chao Wang, Jamie K. Teer +23

    Maqola20213 iqtibos
    ABI

  18. Antibody drug conjugate: the “biological missile” for targeted cancer therapy

    Zhiwen Fu, Shijun Li, Sifei Han +2

    Sharh maqola20223 iqtibos
    ABI

  19. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer

    Feifei Li, Sheng Liu

    Sharh maqola20223 iqtibos
    ABI

  20. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

    Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas +5

    Maqola20162 iqtibos
    ABI

  21. CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?

    María C. Ramello, Eric B. Haura, Daniel Abate‐Daga

    Maqola20172 iqtibos
    ABI

  22. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells

    Jake Moscarelli, David J. Zahavi, Rachael Maynard +1

    Sharh maqola20222 iqtibos
    ABI

  23. Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) Could Offer a Potent Innovative Immunotherapeutic Tool Against Multiple Myeloma

    Manh-Cuong Vo, Sunghoon Jung, Van‐Tan Nguyen +6

    Maqola20232 iqtibos
    ABI

  24. Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy

    Min Yang, Yu Chen, Li Zhu +5

    Sharh maqola20242 iqtibos
    ABI

  25. Ex vivo pulsed dendritic cell vaccination against cancer

    Yangzhuo Gu, Xing Zhao, Xiangrong Song

    Sharh maqola20202 iqtibos
    ABI